Patients receiving care for advanced cancer at Moores Cancer Center at UC San Diego Health were more likely to survive or experience a longer period without their disease progressing if they received personalised cancer therapy, reported University of California San Diego School of Medicine researchers.
The study was published in the online issue of journal Nature Communications.
Led by Razelle Kurzrock, MD, director of the Center for Personalised Cancer Therapy at Moores Cancer Center and senior author of the study, a multidisciplinary molecular tumour board was established to advise treating physicians on the course of care using an individual patient's molecular tumour makeup to design precision medicine strategies.
"Patients who underwent a molecular tumour board-recommended therapy were better matched to genomic alterations in their cancer and had improved outcomes," said Kurzrock.